Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Shanghai IASO Biotechnology

Main focus: Gene editing for the treatment of cancer

Company stage: Clinical

Diseases: T- and B-cell malignancies

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Shanghai and Nanjing, China

Website: http://www.iasobio.com/

Pipeline: http://www.iasobio.com/proline.php

Shanghai IASO Biotechnology develops next generation allogeneic CAR-T cell therapies and uses CRISPR to make the CAR-T cells fratricide-resistent. The company is currently developing multiple pre-clinical programmes using CRISPR, to treat T- and B-cell malignancies.

Shanghai IASO Biotechnology Co., Ltd

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: Shanghai IASO Biotechnology

Search CRISPR Medicine